30 closest matches · ranked by relevance
Superficial Siderosis
Primary: Number of Participants Who Show Stability, Improvement or Decline in Self Reported Hearing — 13; 18; 0 Participants
Siderosis · Neurological Disorder · Rare Diseases
Primary: Hearing Evaluation - Pure Tone Audiometry — 57.3 decibel hearing level
Thalassemia, Non-transfusional-dependent Thalassemia (NTDT), Myeloplastic Dysplasia (MDS), Other Anemia
Primary: Percentage of Participants With Cardiac and Liver Iron Overload. — 10; 22; 4; 0 Percentage of participants
Iron Overload · Excessive Body Iron Burden
Primary: Hepatic Iron Content in the Liver Using Liver Biopsy — 19.8 mcg
Sinusoidal Obstruction Syndrome · Complications of Bone Marrow Transplant
Primary: Sensitivity and Specificity of US for VOD/SOS — 80; 93 percentage of participants
Restless Legs
Primary: Duration Off Treatment — 6; 3; 2; 0 participants
Radiation Induced Fibrosis to the Head and Neck
Primary: Improvement in Neck Fibrosis — 13; 13 participants
Meniere's Disease
Primary: Vestibular "Endolymphatic Hydrops (EH)" — 0; 4; 2 participants
Pancreatic Cancer
Primary: To Determine the Sensitivity High Resolution Magnetic Resonance Imaging With Lymphotrophic Superparamagnetic Nanoparticles to Identify Small and Otherwise Undetectable…
Parkinson's Disease
Primary: Number of Participants With Serious Adverse Events — 0; 0; 0 Participants
Iron Overload
Primary: Per Subject Evaluable DICOM Data Sets From Liver MRI — 21 Participants
Iron Overload Due to Repeated Red Blood Cell Transfusions
Primary: The Percentage of Patients in Each Treatment Group Who Experience Post-dose Increases in Liver Enzyme Levels That Are Considered a Safety Concern. — 0; 0; 0; 0…
Impaired Renal Function
Primary: Area Under the Plasma Concentration-time Curve (AUC) of SSP-004184 — 445892.7; 932688.3; 1531185.8; 1261081.6 ng*hr/ml
Aortic Stenosis
Primary: Transcranial Doppler(TCD) Microembolic Signals During Surgical Aortic Valve Replacement Surgery — 354 units on a scale
Porphyria Cutanea Tarda
Primary: Number of Participants Showing Reduction or Elimination of Skin Blistering — 0; 8 participants
Rheumatologic Disease
Primary: Flow Mediated Dilatation (FMD)-Diameter of Artery — 3.79; 3.78 mm
Restless Legs Syndrome
Primary: Mean Change From Baseline to Day 84 for International Restless Leg Syndrome Study Group (IRLSSG) Scale — -2.4; -14.3; -16.0 units on a scale
Thalassemia Major With Severe Transfusional Iron Overload
Primary: Number of Participants With Improvement in Liver Iron Concentration — 3 Participants
Sickle Cell Disease · Iron Overload · Hemolytic Anemia
Primary: The Number of Participants With Adverse Events (AEs) in the First 24 Weeks of Treatment — 30; 17; 30; 8 participants
Central Nervous System Lymphoma · Malignant Glioma · Metastatic Malignant Neoplasm in the Brain
Primary: Utility of Femumoxytol and Gadolinium Based Contrast Agents for Improved Imaging Biomarkers of Malignant Brain Tumors in a Single Session by Comparing Dynamic Contrast…
Beta-thalassemia · Iron Overload
Primary: Magnetic Resonance Imaging (MRI) T2* and Absolute Change From Baseline in MRI T2* — 9.92; 11.73; 1.77; 11.93 milliseconds (msec)
Scleroderma
Primary: Mean Skin Stiffness — 2.68; 2.07; 2.23; 2.27 meters per second — p=0.005
Osteonecrosis
Primary: Signal to Noise Ratio (SNR) — 33.82; 129.56 dB — p=0.002
Hidradenitis Suppurativa
Primary: HS Physician Local Improvement Assessment - PAIN — 7; 7; 2 Participants
Acute Spinal Cord Injury
Primary: Feasibility of Intraoperative Contrast-enhanced Ultrasound in Acute Traumatic Spinal Cord Injury - Number of Participants With Successful Intraoperative…
Sepsis
Primary: Mortality — 11 Participants
Parkinson Disease · REM Sleep Behavior Disorder · Healthy
Primary: Change in Sensitivity of QSM MR Imaging From Baseline MR Imaging to 24 Month MR Imaging — 379.5896; 314.1832; 561.1894; 288.1832 ppb — p=0.66
Iron Deficiency Anaemia · Iron Deficiency Anemia
Primary: Change in Hemoglobin (Hb) From Baseline to Week 8 — 2.49; 2.49 g/dL
Sickle Cell Disease
Primary: Number of Participants With Adverse Events After Start of ICL670 — 131; 49; 1; 2 participants
Sickle Cell Disease
Primary: Cmax for Serum Deferiprone and Deferiprone 3-O-glucuronide — 17.56; 32.95 μg/mL